1. Home
  2. SIBN vs ODTX Comparison

SIBN vs ODTX Comparison

Compare SIBN & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SI-BONE Inc.

SIBN

SI-BONE Inc.

N/A

Current Price

$23.05

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Odyssey Therapeutics Inc. Common Stock

ODTX

Odyssey Therapeutics Inc. Common Stock

N/A

Current Price

$19.46

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SIBN
ODTX
Founded
2008
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
SIBN
ODTX
Price
$23.05
$19.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
8
Target Price
$26.78
★ $34.67
AVG Volume (30 Days)
★ 876.7K
285.5K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 41.33
N/A
EPS
★ N/A
N/A
Revenue
★ $67,301,000.00
N/A
Revenue This Year
$15.53
N/A
Revenue Next Year
$15.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 21.53
N/A
52 Week Low
$11.48
$15.10
52 Week High
$25.92
$29.05

Technical Indicators

Market Signals
Indicator
SIBN
ODTX
Relative Strength Index (RSI) 52.59 47.95
Support Level $18.51 $18.87
Resistance Level $25.92 $19.60
Average True Range (ATR) 1.47 1.69
MACD -0.21 0.03
Stochastic Oscillator 55.62 30.57

Price Performance

Historical Comparison
SIBN
ODTX

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

About ODTX Odyssey Therapeutics Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

Share on Social Networks: